SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis
Prostate cancer is one of the most common malignancies worldwide, showing a wide range of clinical behaviors. Therefore, several treatment options arise out of the diagnosis “prostate cancer”. For this reason, it is desirable to find novel prognostic and predictive markers. In former studies, we sho...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/13/13/2211 |
| _version_ | 1827735002913177600 |
|---|---|
| author | Fidelis Andrea Flockerzi Johannes Hohneck Matthias Saar Rainer Maria Bohle Phillip Rolf Stahl |
| author_facet | Fidelis Andrea Flockerzi Johannes Hohneck Matthias Saar Rainer Maria Bohle Phillip Rolf Stahl |
| author_sort | Fidelis Andrea Flockerzi |
| collection | DOAJ |
| description | Prostate cancer is one of the most common malignancies worldwide, showing a wide range of clinical behaviors. Therefore, several treatment options arise out of the diagnosis “prostate cancer”. For this reason, it is desirable to find novel prognostic and predictive markers. In former studies, we showed that THSD7A expression is associated with unfavorable prognostic parameters in prostate cancer and is linked to a high expression of focal adhesion kinase (FAK). Recently, scavenger receptor class A member 5 (SCARA5) was reported to be the downstream gene of THSD7A in esophageal squamous cell carcinoma. SCARA5 is believed to play an important role in the development and progression of several different tumor types. Most studies describe SCARA5 as a tumor suppressor. There is also evidence that SCARA 5 interacts with FAK. To examine the role of SCARA5 as a potential biomarker in prostate cancer, a total of 461 prostate cancers were analyzed via immunohistochemistry using tissue microarrays. Furthermore, we compared the expression level of SCARA5 with our previously collected data on THSD7A and FAK. High SCARA5 expression was associated with advanced tumor stage (<i>p</i> < 0.001), positive nodal status (<i>p</i> < 0.001) and high Gleason-score (<i>p</i> < 0.001). At least, strongly SCARA5-positive cancers were associated with THSD7A-positivity. There was no significant association between SCARA5 expression level and FAK expression level. To our knowledge, we are the first to investigate the role of SCARA5 in prostate cancer and we demonstrated that SCARA5 might be a potential biomarker in prostate cancer. |
| first_indexed | 2024-03-11T01:44:09Z |
| format | Article |
| id | doaj.art-9544a788d5094d1fab6e2eae5ea5e30d |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-11T01:44:09Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-9544a788d5094d1fab6e2eae5ea5e30d2023-11-18T16:21:33ZengMDPI AGDiagnostics2075-44182023-06-011313221110.3390/diagnostics13132211SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor PrognosisFidelis Andrea Flockerzi0Johannes Hohneck1Matthias Saar2Rainer Maria Bohle3Phillip Rolf Stahl4Department of Pathology, Saarland University Medical Center, 66424 Homburg, GermanyDepartment of Pathology, Saarland University Medical Center, 66424 Homburg, GermanyDepartment of Urology and Pediatric Urology, University Hospital, 52074 Aachen, GermanyDepartment of Pathology, Saarland University Medical Center, 66424 Homburg, GermanyDepartment of Pathology, Saarland University Medical Center, 66424 Homburg, GermanyProstate cancer is one of the most common malignancies worldwide, showing a wide range of clinical behaviors. Therefore, several treatment options arise out of the diagnosis “prostate cancer”. For this reason, it is desirable to find novel prognostic and predictive markers. In former studies, we showed that THSD7A expression is associated with unfavorable prognostic parameters in prostate cancer and is linked to a high expression of focal adhesion kinase (FAK). Recently, scavenger receptor class A member 5 (SCARA5) was reported to be the downstream gene of THSD7A in esophageal squamous cell carcinoma. SCARA5 is believed to play an important role in the development and progression of several different tumor types. Most studies describe SCARA5 as a tumor suppressor. There is also evidence that SCARA 5 interacts with FAK. To examine the role of SCARA5 as a potential biomarker in prostate cancer, a total of 461 prostate cancers were analyzed via immunohistochemistry using tissue microarrays. Furthermore, we compared the expression level of SCARA5 with our previously collected data on THSD7A and FAK. High SCARA5 expression was associated with advanced tumor stage (<i>p</i> < 0.001), positive nodal status (<i>p</i> < 0.001) and high Gleason-score (<i>p</i> < 0.001). At least, strongly SCARA5-positive cancers were associated with THSD7A-positivity. There was no significant association between SCARA5 expression level and FAK expression level. To our knowledge, we are the first to investigate the role of SCARA5 in prostate cancer and we demonstrated that SCARA5 might be a potential biomarker in prostate cancer.https://www.mdpi.com/2075-4418/13/13/2211SCARA5prostate cancerTHSD7A |
| spellingShingle | Fidelis Andrea Flockerzi Johannes Hohneck Matthias Saar Rainer Maria Bohle Phillip Rolf Stahl SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis Diagnostics SCARA5 prostate cancer THSD7A |
| title | SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis |
| title_full | SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis |
| title_fullStr | SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis |
| title_full_unstemmed | SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis |
| title_short | SCARA5 Is Overexpressed in Prostate Cancer and Linked to Poor Prognosis |
| title_sort | scara5 is overexpressed in prostate cancer and linked to poor prognosis |
| topic | SCARA5 prostate cancer THSD7A |
| url | https://www.mdpi.com/2075-4418/13/13/2211 |
| work_keys_str_mv | AT fidelisandreaflockerzi scara5isoverexpressedinprostatecancerandlinkedtopoorprognosis AT johanneshohneck scara5isoverexpressedinprostatecancerandlinkedtopoorprognosis AT matthiassaar scara5isoverexpressedinprostatecancerandlinkedtopoorprognosis AT rainermariabohle scara5isoverexpressedinprostatecancerandlinkedtopoorprognosis AT philliprolfstahl scara5isoverexpressedinprostatecancerandlinkedtopoorprognosis |